source
- FDA rejects Capricor's Duchenne cell therapy citing serious data integrity violationsThe Food and Drug Administration issued a second rejection of Capricor Therapeutics' cell therapy, deramiocel, aimed at treating Duchenne muscular dystrophy. The agency said the revised application…
- Compass Pathways and Usona Institute vie for first FDA approval of a psilocybin depression therapyCompass Pathways and Usona Institute are both positioning themselves to become the first company with an FDA-approved psilocybin therapy for treatment-resistant depression. Compass has long been s…